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AbstrACt
Introduction The effect of early and sustained 
administration of daily probiotic therapy on patients 
admitted to the intensive care unit (ICU) remains uncertain.
Methods and analysis The Restoration Of gut microflora 
in Critical Illness Trial (ROCIT) study is a multicentre, 
randomised, placebo- controlled, parallel- group, two- sided 
superiority trial that will enrol 220 patients in five ICUs. 
Adult patients who are within 48 hours of admission to 
an ICU and are expected to require intensive care beyond 
the next calendar day will be randomised in a 1:1 ratio to 
receive early and sustained Lactobacillus plantarum 299v 
probiotic therapy in addition to usual care or placebo in 
addition to usual care. The primary endpoint is days alive 
and out of hospital to day 60.
Ethics and dissemination ROCIT has been approved by 
the South Metropolitan Health Service Human Research 
Ethics Committee (ref: RGS00000004) and the St John of 
God Health Care Human Research Ethics Committee (ref: 
1183). The trial results will be submitted for publication in 
a peer- reviewed journal.
trial registration number Australian and New Zealand 
Clinical Trials Registry (ANZCTR12617000783325); Pre- 
results.
IntroduCtIon
Patients admitted to the intensive care unit 
(ICU) commonly develop dysbiosis, an imbal-
ance in intestinal commensal microflora 
characterised by a decrease in the diversity of 
commensal gut bacteria and an overgrowth 
of pathogenic species that is associated 
with increased morbidity and mortality.1–5 
Probiotics are live microorganisms that, when 
administered in adequate amounts, confer a 
beneficial effect on the health of the host.6 
Probiotic therapy may reduce the incidence 
of surgical- site infections and other postop-
erative complications in patients undergoing 
surgery.7 In patients admitted to the ICU, 
probiotic therapy may reduce the risk of noso-
comial infections and reduce the hospital 
length of stay (LOS).8–11 A recent meta- 
analysis of 30 randomised controlled trials 
(RCTs) concluded that probiotic therapy 
was associated with a significant reduction 
in infection, but had no significant effect on 
mortality.12 However, study design heteroge-
neity and risk of bias have precluded strong 
strengths and limitations of this study
 ► Early and sustained administration of study drug 
until the determination of the primary outcome (day 
60).
 ► Pragmatic study design including broad eligibility 
criteria and administration in a usual care setting.
 ► Sample size calculation informed by consumers and 
local baseline data.
 ► Blinded adjudication of outcomes including nosoco-
mial infection.
 ► A requirement to deliver and assess the delivery of 
study drug beyond intensive care unit and hospital 
discharge.
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Table 1 Trial eligibility criteria
Inclusion criteria
1. Adult patient within 48 hours of admission to an ICU
2. Expected to require ICU- level care beyond the next calendar day
Exclusion criteria
1. <18 years of age
2. Absolute contraindication to receiving medication via the enteral route
3. Known to be receiving probiotic therapy at the time of index hospitalisation
4. Acute pancreatitis as a cause or complication of current admission
5. Immunosuppression (defined as chemotherapy within the preceding 4 weeks or receiving ≥1.5 mg/kg 
methylprednisolone daily or equivalent)
6. Neutropenia (neutrophil count ≤1×109/L)
7. Prosthetic heart valve or permanent pacemaker
8. Death is deemed to be inevitable as a result of the current acute illness AND either the treating 
clinician, the patient or the substitute decision- maker, are not committed to full active treatment
9. Enrolment is not considered in the patient’s best interest
10. Previously enrolled in ROCIT
11. Unlikely to be residing near or visiting a study centre in 60 days
12. Participating in a competing interventional study
13. Pregnancy
14. Admitted to hospital from a high- level nursing facility or rehabilitation facility
ICU, intensive care unit; ROCIT, Restoration Of gut microflora in Critical Illness Trial.
recommendations for the use of probiotics in current crit-
ical care nutrition guidelines.13 14 Furthermore, existing 
RCTs have generally not addressed the attributable risk 
of nosocomial infection, morbidity and mortality that 
persists after discharge from an index ICU admission.15
Among available probiotic strains, Lactobacillus plan-
tarum 299v (Lp299v) is a strong candidate therapy to 
improve outcomes in critically ill patients. Adminis-
tration results in intestinal colonisation and survival 
of the probiotic through the entire gastrointestinal 
tract, regardless of gastric pH.16–18 In otherwise healthy 
smokers, Lp299v therapy decreases markers of inflam-
mation and oxidative stress.19 In a recent landmark trial, 
Lp299v therapy reduced sepsis and death in rural Indian 
newborns.20 In critically ill patients admitted to the ICU, 
Lp299v therapy exhibits similar suppression of oropha-
ryngeal colonisation with pathogenic bacteria as chlor-
hexidine, reduces colonic colonisation with Clostridiodes 
difficile and attenuates markers of systemic inflamma-
tion.21–23 The possibility of specific benefit from Lp299v 
therapy in patients admitted to the ICU is supported by 
a meta- analysis reporting that although probiotic therapy 
appears to reduce nosocomial infection in critical illness, 
a significant benefit is only evident in trials administering 
Lp299v.12 However, recent evidence suggests that probi-
otic lactobacilli strains can directly cause bacteraemia 
when administered to patients in ICU and the safety and 
efficacy of Lp229v in adult patients admitted to the ICU 
remains uncertain.24
The Restoration Of gut microflora in Critical Illness 
Trial (ROCIT) was designed to assess whether, in adult 
patients admitted to the ICU, early and sustained daily 
administration of probiotic therapy using Lp299v, 
compared with placebo, is associated with an increase in 
days alive and out of hospital to day 60 (DAOH60).
This report describes the ROCIT protocol and statis-
tical analysis plan.
MEthods And AnAlysIs
trial design
ROCIT is a multicentre, placebo- controlled, parallel- 
group, two- sided superiority trial that will randomly 
allocate patients admitted to the ICU in a 1:1 ratio. 
Participants will receive probiotics in addition to usual 
care, or placebo in addition to usual care. ROCIT has 
been designed with reference to the Standard Protocol 
Items: Recommendations for Interval Trials checklist 
and is informed by consumer consultation (Consumer 
and Community Health Research Network, University 
of Western Australia, WA).25 The trial was prospectively 
registered on the Australian and New Zealand Clinical 
Trials Registry.
setting and participants
ROCIT will enrol a total of 220 participants from five 
study sites in Western Australia (see the supplementary 
appendix for the study site list). Eligible patients are those 
within 48 hours of ICU admission and who are expected 
to remain in the ICU beyond the next calendar day. ICU 
admission includes admission to a high- dependency 
area, defined as an area capable of providing invasive 
monitoring and a nursing ratio of no greater than 1:2. 
Patients who will be excluded include those with an abso-
lute contraindication to receiving medication via the 
enteral route and those with one or more risk factors for 
treatment- associated adverse effects including recent or 
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Figure 1 Study drug bottle labelling. CFU, colony- forming unit; ROCIT, Restoration Of gut microflora in Critical Illness Trial.
ongoing immunosuppressive therapy.26 The complete 
inclusion and exclusion criteria are provided in table 1. 
The first patient was enrolled on 28 July 2017 and 
recruitment to the planned sample size is expected to be 
completed in early 2020.
randomisation and blinding
Eligible participants are identified by members of the 
study and clinical teams at participating sites. This prag-
matic approach, embedded in clinical care, will maximise 
recruitment. The variable- block randomisation algo-
rithm is stratified by site and has been generated using 
a web- based randomisation interface by an unblinded 
pharmacist with no direct involvement in patient care, 
data collection or analysis.27 Allocation concealment is 
maintained by assigning a unique number to each bottle 
of study drug (figure 1). The randomisation list is kept 
by the unblinded pharmacist who is also available for 
unblinding at the request of the patient or treating team. 
After trial enrolment, the participant is assigned the next 
available subject number, corresponding to the unique, 
consecutively numbered bottle of study drug.
The active study drug and the placebo are prepared 
in identically packaged capsules and bottles by a certi-
fied facility (Health World, Northgate, Queensland, 
Australia). All treating team members, participants, study 
staff and outcome adjudicators are blinded to the treat-
ment allocation.
study treatments
Immediately after enrolment, a dose of study drug 
is administered. A single capsule of the study drug is 
then prescribed daily, beginning the next calendar day. 
Instructions are provided to continue once daily adminis-
tration, including after index ICU and hospital discharge, 
until day 60, (ie, the completion of the 60- capsule bottle). 
A standard operating procedure is provided to bedside 
clinical staff for the preparation and administration of 
study drug and contains instructions for nasogastric tube 
administration for participants unable to swallow capsules 
(see online supplementary appendix figure 1). At the 
time of hospital discharge, participants are provided with 
a study diary to record daily study drug administration 
(see online supplementary appendix figure 2). Partici-
pants are asked to return the completed diary along with 
the study drug bottle and any remaining capsules on day 
60.
Participants randomly allocated to the active study arm 
receive a daily capsule with 20×109 colony- forming units 
(CFUs) of Lp299v. Participants randomly allocated to the 
placebo arm receive an identical- looking capsule of malto-
dextrin. Independent batch testing of the study drug 
conducted by members of the study team and provided 
by the unblinded pharmacist confirmed >20×109 Lp299v 
CFU and unrecordable Lp299v CFU in the active and 
placebo capsules, respectively.
The study drug is transported under controlled and 
recorded refrigerated conditions from the manufacturer 
to study sites and stored under refrigerated and moni-
tored conditions during the hospital stay. A cool bag is 
provided to patients for the transport of the study drug 
on hospital discharge and patients are advised to refrig-
erate the study drug as soon as they arrive home. A clin-
ical trial notification for ROCIT has been lodged with the 
Australian Government Therapeutic Goods Administra-
tion (ref: CT-2017- CTN-03 603–1).
Concomitant therapies
Participants are requested to refrain from initiating 
any probiotic treatment other than the study treatment 
during the 60 days of study participation. Probiotics are 
not on the hospital formulary of any of the five study sites 
participating ROCIT. All other care is at the discretion of 
the treating teams.
discontinuation
Study drug may be discontinued at the request of the 
participant or treating clinician at any stage if the partici-
pant or treating clinician suspects an adverse reaction or 
that continued participation is not in the best interest of 
the participant. A suspected or confirmed severe adverse 
drug reaction will result in immediate and permanent 
discontinuation of the study medication. Study drug will 
also be discontinued permanently if L. plantarum is grown 
from a sterile site or is the predominant growth from a 
non- sterile site.
outcomes
The flow of participants in the study will be reported 
according to Consolidated Standards of Reporting Trials’ 
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Figure 2 Proposed reporting of the flow of trial participants. ROCIT, Restoration Of gut microflora in Critical Illness Trial.
criteria (figure 2).28 The primary outcome is DAOH60. 
DAOH is a validated measure that includes death, LOS 
in hospital, need for ongoing rehabilitation and the 
occurrence and duration of hospital readmission.29–32 
Days spent in a rehabilitation facility or high- level nursing 
facility to day 60 are considered as days in the hospital. 
Participants who die prior to day 60 will be recorded as 
having zero DAOH60.
33
Secondary endpoints include the occurrence of 
specified nosocomial infections (hospital- acquired 
pneumonia, ventilator- associated pneumonia, C. difficile- 
associated diarrhoea, surgical- site infection, urinary tract 
infection and blood stream infection) defined according 
to Centre for Disease Control criteria (see online supple-
mentary appendix table 1).34 Screening for nosocomial 
infection will occur by identifying each episode of initi-
ation or change of antibiotic to day 60 and will then be 
assessed independently by two blinded infectious diseases 
specialist clinicians by review of the medical records. 
Any disagreement will be resolved by consensus. Other 
secondary endpoints include antibiotic- free days to day 
60, ICU and hospital LOS, and ICU, hospital and 60- day 
mortality. Quality of life will be assessed using the five- 
level EuroQol five- dimension questionnaire at day 60, 
administered via telephone by blinded research staff at 
each study site (table 2).
data collection and management
Trained research coordinators will collect data at each 
site using a study- specific case report form. Study data 
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Table 2 Study data to be collected
Time point Study data
Screening  ► Date of screening
 ► Inclusion and exclusion criteria
 ► Reason, if not enrolled
 ► Study number and patient initials for enrolled participants
Baseline  ► Date and time of randomisation
 ► Date and time of ICU admission
 ► Demographic data
 ► ICU admission source and category
 ► Nutrition, acid- suppressive therapy and antibiotics
 ► Admission APACHE II score, diagnostic code and comorbidities
 ► SOFA Score and components
 ► Mechanical ventilation
 ► Vasoactive medication
 ► Renal replacement therapy
Daily during index 
hospitalisation
 ► Patient location (ICU/HDA or ward)
 ► Received study drug
 ► Days of mechanical ventilation, vasoactive medication and renal replacement therapy
 ► Days of antibiotic, antiviral and antifungal medication
 ► New infection diagnosed
Outcome (day 60)  ► Hospital length of stay
 ► Nosocomial infection (hospital- acquired pneumonia, ventilator- associated pneumonia, Clostridium 
difficile- associated diarrhoea, surgical- site infection, urinary tract infection and blood stream infection)*
 ► ICU length of stay
 ► ICU mortality
 ► Hospital mortality
 ► EQ- 5D- 5L
Adverse events  ► Description, timing, causality and resolution of adverse events from randomisation to day 60
Protocol deviations  ► Randomisation of ineligible patients, failure to comply with the study protocol
*The prespecified nosocomial infections will be identified according to the Centre for Disease Control definitions and are provided in the 
online supplementary appendix.
APACHE, Acute Physiology And Chronic Health Evaluation; EQ- 5D- 5L, five- level EuroQol five- dimension questionnaire; HDA, high- 
dependency area; ICU, intensive care unit; SOFA, Sequential Organ Failure Score.
are entered into a Research Electronic Data Capture 
(REDCap) database, a secure, web- based software plat-
form.35 Assessment of the primary outcome will include 
direct phone contact with participants on or shortly after 
day 60 where participants are not known to be hospital-
ised or have died. Details of the occurrence and duration 
of hospital readmissions will be collected during this 
phone call and cross- checked against hospital medical 
records and, if required, general practitioner records. To 
ensure the accuracy and completeness of data, there will 
be prespecified automatic checks and on- site data moni-
toring by the project manager, including 100% source 
data verification for the primary endpoint. Screening, 
baseline, daily, outcome, adverse event and protocol devi-
ation data are provided in table 2. The plans for collecting 
and storing biological specimens for analysis in ancillary 
studies are provided in the supplementary appendix.
sample size and power
A difference of 4 days in DAOH60 is considered mean-
ingful by a specially convened forum of consumers 
including ICU survivors and next- of- kin (Consumer and 
Community Health Research Network, University of 
Western Australia, WA). Baseline DAOH60 has been calcu-
lated using contemporary data from participating hospi-
tals. From these data, a baseline of 37 DAOH60, an SD of 
9 and a two- tailed α =0.05, a trial of 162 participants has 
80% power to detect a difference in DAOH60 of 4 days. 
After inflation for non- normal distribution (20%), with-
drawn consent (5%) and loss to follow- up (5%), the final 
sample size is 220 participants.
statistical analysis plan
The primary analysis will be the intention- to- treat popula-
tion, defined as all eligible and randomised study partic-
ipants, except for those who do not consent to use of 
the data necessary to determine the primary outcome. 
There will be no imputation for missing data. Normally 
distributed data will be presented as mean (SD) and non- 
normally distributed data as median (IQR). Comparisons 
will be performed using Fisher’s exact test for categorical 
data and Student’s t test or the Wilcoxon rank- sum test 
for normally and non- normally distributed data, respec-
tively. The primary outcome (DAOH60), will be analysed 
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using the Wilcoxon rank- sum test with results presented 
as a comparison of medians (IQR). A two- sided p value 
of <0.05 will be considered statistically significant. Hetero-
geneity between prespecified subgroups, identified at 
baseline, will be assessed by fitting an interaction term 
between treatment and subgroup.
The three subgroup pairs will be: patients with sepsis 
versus those without sepsis; emergency versus elective ICU 
admissions; and surgical versus medical admissions. A per- 
protocol analysis will be conducted including all partici-
pants with reported adherence to the study medication 
for >80% of their total study duration. Planned substudies 
include longitudinal evaluation of faecal microbiome and 
blood metabolome, and if there is a statistically significant 
difference in the primary outcome, then an economic 
evaluation of the cost- effectiveness of the intervention will 
be there. All analyses will be conducted using STATA/SE 
V.13.
Patient and public involvement
The primary outcome was chosen on the basis of 
published evidence of the importance placed by patients 
on days spent at home.36 Consideration of additional 
outcome measures was made in conjunction with an 
ICU consumer forum convened from the Consumer 
and Community Health Research Network (University of 
Western Australia, WA). Study participants are offered the 
opportunity to have the published study results supplied 
to them directly and to be unblinded after the final deter-
mination of all study outcome measures. The published 
manuscript of the primary outcome will be made avail-
able to the Consumer and Community Health Research 
Network for dissemination among stakeholders.
data monitoring committee
The data monitoring committee (DMC) has expertise in 
critical care, infectious diseases and trial design but is not 
otherwise involved in the care of study participants and 
is independent of competing interests. The members are 
Nolan McDonnell (BHB, MBChB, FANZCA, MClinRes), 
Claire Italiano (MBBS, FRACP, MPHTM) and Ravi 
Sonowane (MBBS, FCICM, MPH). The DMC has reviewed 
and approved the study protocol and will review all serious 
adverse events as they occur. The ROCIT management 
committee will inform the DMC of any accumulating 
external evidence of relevance to the ongoing conduct of 
the study as soon as practicable. No interim analyses are 
planned but the DMC will reserve the right to conduct an 
interim analysis or advise suspension or termination of 
ongoing enrolment to the study.
Adverse events
Events that are a part of the natural history of the primary 
disease process or expected complication of critical 
illness will not be reported as serious adverse events.37 
All adverse events considered to be potentially causally 
related to the trial, and all serious adverse events will be 
reported (online supplementary appendix table 2).
EthICs And dIssEMInAtIon
Ethics approval
ROCIT has been approved by the South Metropolitan 
Health Service Human Research Ethics Committee (ref: 
RGS00000004) and the St John of God Health Care 
Human Research Ethics Committee (ref: 1183). The 
approved consent pathways included prospective partic-
ipant consent for study- eligible patients with capacity 
and prospective person responsible acknowledgement 
with deferred consent for patients who lacked capacity. 
Protocol modifications will be submitted to the Human 
Research Ethics Committee review prior to dissemination 
and initiation at trial sites. A copy of the consent form is 
provided in the supplementary appendix.
dissemination
The study results will be submitted for publication in a 
peer- reviewed journal. Study data and statistical code 
can be accessed by contacting the corresponding author. 
Requests for access will be reviewed by the named authors 
on a case- by- case basis.
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